Patients who develop cytokine release syndrome after chimeric antigen receptor T-cell therapy for autoimmune disease ...

Sequencing and re-expressing B cell receptors from lymphoma tissue of rheumatoid arthritis patients reveals polyreactive and ...

Laboratory experiments with human tonsil-derived fibroblasts show that senescent lymphoid stromal cells suppress B cell ...

Artiva Biotherapeutics Inc. ARTV announced it will halt further clinical development of its lead cell therapy candidate, ...

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) announced on October 27, 2026, that it will discontinue development of its AlloNK ...

Artiva Biotherapeutics said it will eviscerate its workforce 94% and evaluate strategic options after two patients treated ...

Four CD20xCD3 T-cell engagers post strikingly similar response rates in B-cell lymphoma, yet one remains EU-approved and US-blocked. Here's what actually distinguishes them.

Stanford's Richard Lafayette discusses 36-week povetacicept data in IgA nephropathy, including proteinuria, hematuria, and safety findings. Povetacicept, a dual inhibitor of B-cell activating factor ...

When treatment is urgent, are there clues to foresee the outcome?When you are told of a relapse and must start the next treatment as soon as possible, the first thing many people want to know is, ...

Identify cost-efficient trial locations, investment opportunities and enrollment trends to sharpen strategy and gain a competitive advantage.Dublin, Oct. (GLOBE NEWSWIRE) -- "Diffuse Large B-Cell ...

Artiva Biotherapeutics (ARTV) shares fell 31% in Tuesday afternoon trading after the drugmaker said it will discontinue further development of AlloNK, its cell therapy candidate b ...

The researchers found that GaGCLs share several important features with mammalian germinal centers. B cells within these structures underwent extensive proliferation and apoptosis, while B cells ...